As glycaemic variability on the one hand and hypoglycaemia on the other are associated with oxidative stress and inflammation, they are likely, in type-1 diabetic patients, to affect the oxidation of lipoproteins and HDL function, by altering their anti-atherogenic properties. The aim of this study is thus to determine, in patients with Type 1 Diabetic (T1D) who will wear a glycaemic Holter for 1 week, the glycaemia parameters (mean glycaemia, duration of hypoglycaemia, duration of hyperglycaemia, mean amplitude of glycaemic excursions) associated with proatherogenic alterations in lipoproteins, in particular: * LDL oxidation * HDL oxidation and alterations of HDL function (anti-inflammatory capacity, antioxidant capacity)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Average blood glucose
Timeframe: through study completion, an average of 7 days
Time hypoglycemia
Timeframe: through study completion, an average of 7 days
Time hyperglycemia
Timeframe: through study completion, an average of 7 days
Amplitude of glycemic variations
Timeframe: through study completion, an average of 7 days